Cited by 343Cancer-related Molecular PathwaysChromatin Remodeling and CancerGenomics and Chromatin Dynamics

Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth

Open access
Sellers, William R., Novitch, Bennett G., Miyake, Satoshi, Heith, Agnieszka, Otterson, Gregory A., Kaye, Frederic J., Lassar, Andrew B., Kaelin, William G.·1998·Genes & Development

Abstract

The retinoblastoma tumor suppressor protein (pRB) can inhibit cell cycle progression and promote differentiation. pRB interacts with a variety of transcription factors, including members of the E2F and C-EBP protein families and MyoD, and can either repress or activate transcription depending on the promoter under study. These biological and biochemical activities of pRB have been mapped previously to a core domain, referred to as the pRB pocket. Using a panel of synthetic pRB pocket mutants, we found that the acute induction of a G 1/S block by pRB is linked to its ability to both bind to E2F and to repress transcription. In contrast, these functions were not required for pRB to promote differentiation, which correlated with its ability to activate transcription in concert with fate-determining proteins such as MyoD. All tumor-derived pRB mutants tested to date failed to bind to E2F and did not repress transcription. Despite an inability to bind to E2F, pRB mutants associated with a low risk of retinoblastoma, unlike high-risk mutants, retained the ability to activate transcription and promote differentiation. Thus, the pRB pocket participates in dual tumor suppressor functions, one linked to cell cycle progression and the other to differentiation control, and these functions can be genetically and mechanistically dissociated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.12.1.95

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some mutant RB forms from low-penetrance retinoblastoma families are deficient in E2F binding but retain the ability to induce differentiation of tumour cells.

    “some mutant forms of RB from families with low penetrance retinoblastoma were deficient in E2F binding but retained the ability to induce the differentiation of tumour cells.”
  • Similar observations of mutant RB retaining pro-differentiation activity have been made for osteosarcoma.

    “similar observations have been made for osteosarcoma70–72.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 66 · Cited by 343

Authors
Sellers, W. R., Novitch, B. G., Miyake, S., Heith, A., Otterson, G. A., Kaye, F. J., Lassar, A. B., & Kaelin, W. G.
Affiliations
Harvard University (US)
Venue
Genes & Development
Published
1998-01-01
Volume
12
Issue
1
Pages
95-106
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2109829350
Cited by
343
References
66
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 7 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 9 · 2015: 10 · 2014: 6 · 2013: 12 · 2012: 14
Type
posted content
Language
en
Open access
Locations
  • Genes & Development (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • James S. McDonnell Foundation
  • National Institutes of Health
  • National Cancer Institute
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
retinoblastoma protein, transcriptional activation, transcriptional repression, cell cycle arrest, cell differentiation, tumor suppression, MyoD, C/EBP
MeSH terms
Carrier Proteins, Cell Differentiation, Cell Division, DNA-Binding Proteins, Humans, Nuclear Proteins, Phosphoproteins, Proteins, Retinoblastoma, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Transcriptional Activation, Retinoblastoma Protein, G1 Phase, S Phase, Mutagenesis, Site-Directed, Cell Cycle Proteins, Transcription Factor DP1, E2F Transcription Factors, Retinoblastoma-Like Protein p130, Retinoblastoma-Like Protein p107, Retinoblastoma-Binding Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review